Mindray, a global medical solutions provider, has achieved an impressive AA rating for its Environmental, Social and Governance (ESG) practices from Morgan Stanley Capital International (MSCI), making it the highest-rated A-share listed company in the market. This recognition solidifies Mindray’s position as a leader in ESG management, particularly in the medical device industry.
According to MSCI’s latest ESG rating report, Mindray’s sustainable development efforts in the social and governance domains have led to this rating upgrade. The company’s commitment to placing its employees at the center of its sustainable development strategy has been instrumental in this achievement. Mindray’s focus on attracting top talent from universities worldwide and cultivating a diverse global talent team has resulted in a consistent increase in the number of employees over the past three years. Diversity, equality, and inclusion are core values for Mindray, and the company has implemented various systems and measures to promote diversity throughout its staff. With 51 overseas subsidiary companies, Mindray employs 100% local staff in 29 countries.
Mindray has also excelled in product quality and safety, as recognized by MSCI. The company has established a comprehensive quality management system that integrates all aspects of its business functions, ensuring the quality and safety of its products. This commitment to excellence has placed Mindray at the forefront of product quality management in the industry.
In terms of corporate governance and business ethics, Mindray has received affirmation from MSCI for its protection of whistleblowers and regular compliance audits on anti-corruption practices. The company upholds complete honesty and trustworthiness in all its operations, adhering strictly to laws and regulations related to anti-corruption, conflicts of interest, fraud, monopoly, and unfair competition. Mindray conducts regular ethics audits and encourages employees, suppliers, and other stakeholders to report any illegal or disciplinary actions related to the company. The protection of whistleblowers is a top priority for Mindray, as it aims to safeguard their rights and interests.
Mindray’s commitment to sustainability is further evident in its fifth Sustainability Report, which highlights the company’s progress in six key areas of its sustainable development strategy. For the first time, Mindray has set a carbon emission reduction target, aiming to reduce its carbon emissions intensity by 25% by 2030 compared to the baseline from 2021. The company has also implemented corresponding plans to accelerate its low-carbon transformation efforts across its operations.
Li Xiting, Chairman of Mindray, has emphasized the company’s dedication to its core business and continuous improvement in innovation, market expansion, and localization construction. Mindray’s forward-thinking approach ensures that sustainable development strategies remain a top priority, and collaboration with relevant stakeholders is expanded to explore sustainable pathways for the medical industry.
Mindray’s achievement of an AA rating from MSCI further solidifies its position as a global leader in ESG management. The company’s relentless focus on sustainable practices, employee-centric policies, and product quality has set it apart in the medical device industry. Mindray’s commitment to corporate governance and ethical practices fosters trust and transparency, ensuring its stakeholders’ rights and interests are protected. As Mindray continues to prioritize sustainability and collaboration, it is poised to drive the medical industry towards a more sustainable future.
